secwatch.observer — SEC 8-K summary
======================================

Issuer:     RemSleep Holdings Inc. (RMSL)
CIK:        0001412126
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001213900-22-016562
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RemSleep reports cytotoxicity test failures on DeltaWave cannula; new lab to retest
--------------------------------------------------------------------------------

- Two cytotoxicity tests on DeltaWave cannula MD, Angled Adaptor and Flexible Hose failed in early 2022.
- Superior Toxicology & Wellness concluded original testing protocols were flawed and erroneous.
- New third-party lab will conduct cytotoxicity tests with corrected procedures.
- Initial tests by Product Safety Labs in New Jersey; both were failures.
- CEO Tom Wood received letter from Dr. Joe Nieusma on March 25, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412126/000121390022016562/0001213900-22-016562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412126/000121390022016562/ea157712-8k_remsleep.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-016562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer